Table I.
Biologics (N = 141) | Prevalence rate of ISRs, n (%) |
---|---|
Ixekizumab (n = 20) | 11 (55.0) |
Guselkumab (n = 42) | 6 (14.3) |
Adalimumab (n = 11) | 1 (9.1) |
Risankizumab (n = 14) | 1 (7.1) |
Ustekinumab (n = 22) | 0 |
Secukinumab (n = 32) | 0 |
ISRs, Injection site reactions.